87%Confidence
0Views
FDASource
2026-03-02Date
Summary
Amerisource Health Services recalls oxycodone tablets due to defective blister seals that could lead to dosage errors or diversion, presenting both safety and regulatory compliance risks. As a controlled substance, this defect carries additional legal implications and could affect distributor relationships.
Actionable: Review AmerisourceBergen's quality control processes for controlled substances and monitor for potential DEA or FDA regulatory consequences.
AI Confidence: 87%
Data Points
firmAmerisource Health Services LLC
classificationClass II
statusOngoing
distributionNationwide in the USA
productOxycodone Hydrochloride Tablets, USP (CII), 5 mg, 100-Count (10 x 10) blister cards per carton, Rx Only, The drug product contained in this package
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now